TNNI3K

Across TCGA pan-cancer cohorts, TNNI3K mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TNNI3K data layer compared with 20 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TNNI3K mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNNI3K expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where TNNI3K mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.291	1.000	.001	26	view →
LUAD	DFS	Median	III,IV	0.977	0.504	.005	14	view →
LSCC	OS	Median	All	0.923	0.720	.003	13	view →
PDAC	OS	Median	II,III,IV	0.773	0.915	.002	12	view →
GBM	OS	Tertile	All	0.625	0.235	.008	10	view →
CCRCC	OS	Median	All	0.699	1.000	.010	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TNNI3K–HNSC (DFS)

Open the HNSC breakdown →